Skip to main content
Equibles
CRBP logo

CRBP · Corbus Pharmaceuticals Holdings, Inc. · Metrics

Track CRBP — free

Use CRBP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRBP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.39 -0.03 (-0.68%)
Russell 2000 member Rebalance outlook locked
Market Cap
$85.49M
Shares
19.34M
Volume · Oct 21 450.74K Avg daily vol (3M) 828.37K

CRBP metrics

64 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.42
Market cap
$85.49M

Price action

20 metrics
Price change (1W)
-7.5%
Price change (30D)
-42.2%
Price change (3M)
-50.8%
Price change (6M)
-57.1%
Price change (YTD)
-45.7%
Price change (1Y)
-75.8%
Trailing year
Price change (5Y)
—
52-week high
$19.36
52-week low
$4.33
Change from 52-week high
-77.2%
Change from 52-week low
+2.1%
Annualized volatility
78.2%
Annualized volatility (3M)
69.0%
Beta
1.3
RSI (14D)
21.1
Price vs SMA 50
-45.5%
Price vs SMA 200
-49.7%
Avg volume (3M)
828,365
Relative volume
0.6
Average dollar volume
$6.51M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
19.34M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.8
reciprocal yield 119.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-119.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
3.6×
reciprocal yield 28.0%
EV / revenue historical average (5Y)
3.6×
reciprocal yield 28.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$106.88M
Net income (TTM)
−$101.90M
Trailing 12 months
Diluted EPS (TTM)
$-6.11
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$8.38

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+58.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-99.7%
Return on assets
-80.2%
Debt / equity
0.0
Current ratio
5.7
EBITDA (TTM)
−$106.68M
Free cash flow (TTM)
—
Quick ratio
5.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$117.94M
Latest balance sheet
Cash & equivalents
$23.37M
Total assets
$126.99M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$86.67M
Capital expenditures (TTM)
$19,000
R&D (TTM)
$90.26M
SG&A (TTM)
—
Stock compensation (TTM)
$6.73M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
107
13F filer change QoQ
-1
Institutional ownership
80.1%
Conviction holders (share of 13F filers)
0.9%
Crowding (high-turnover and private-fund holders)
44.9%
Private-fund adviser ownership
38.2%
Active holders' share change QoQ
-8.6%
Holder tenure
7.8
Price vs estimated holder cost
-50.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.6%

Short interest

3 metrics
Short interest
15.8%
Latest settlement · 3.9 days to cover
Days to cover
3.9d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$283,013
Insider-sentiment score
77 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1595097 CUSIP 21833P301 13F (30d) 13 filings 13 filers Visit website Investor relations